Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

23 Apr, 2021

Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators
Photo by Allan Wadsworth on Unsplash

– Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted with a EUR 20 million (approx. $24 million) seed financing.
– Anavo’s mission is to pioneer systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class.
– The funds will be used to advance a proprietary drug discovery portfolio in oncology and establish a versatile and robust platform to address the target space broadly across multiple indications.
– Anavo’s leadership team, Dr. Birgit Zech and Dr. Gerhard Müller, are building on several years of joint experience in the biopharmaceutical industry and have demonstrated the ability to navigate rapidly emerging sectors in biopharma most recently as co-founders of Gotham Therapeutics.

Biotechnology Life Science Western Europe
Crunchbase icon

Content report

The following text will be sent to our editors: